Management strategies should be tailored to the specific GI symptoms experienced [15, 64]
Other peptides worth comparing: Liraglutide daily GLP-1 agonist, less effective than both but FDA-approved since 2014 Retatrutide triple agonist (GLP-1/GIP/Glucagon), showing up to 24% weight loss in Phase 2 trials AOD-9604 HGH fragment for fat metabolism, much milder effect The Bottom Line Tirzepatide has the edge in raw efficacy and tolerability based on trial data
Healthcare providers monitor for possible risks such as pancreatitis or gallbladder disease, especially in patients with a history of these conditions
When appropriately prescribed and monitored, these regimens contribute to improved satiety, better glycaemic control, and maintenance of functional MM, thereby preventing sarcopenic obesity and reducing the risk of weight regain
Medicine & Science in Sports & Exercise, 26, 1122-1129
Nutritional Deficiencies Are More Common Than Expected Large studies show that approximately 22% of GLP-1 users develop nutritional deficiencies within one year